China Biologic Completes $468 Million Follow-On Offering
On March 7, 2016, China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, completed its follow-on public offering with an aggregate offer size of more than $468 million, consisting of 4,257,000 shares of common stock sold by entities affiliated with Warburg Pincus, the selling stockholders, at a price to the public of $110 per share. China Biologic did not sell any shares of common stock or receive any proceeds from the sale in the offering.
Wilson Sonsini Goodrich & Rosati represented China Biologic and the selling stockholders in connection with the offering. Morgan Stanley & Co. International acted as the sole book-running manager for the offering.
For more information, please see the China Biologic's press release.